XSWXYPSN
Market cap4.93bUSD
Jan 13, Last price
331.00CHF
1D
-2.36%
1Q
-16.94%
Jan 2017
78.92%
Name
Ypsomed Holding AG
Chart & Performance
Profile
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and Ypsomed Diabetes Care. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto injectors, patch injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through biotechnology and pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
Valuation
Title CHF in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | 2015‑03 | |
Income | ||||||||||
Revenues | 548,457 10.25% | 497,460 7.02% | 464,841 15.16% | |||||||
Cost of revenue | 467,394 | 489,115 | 462,398 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 81,063 | 8,345 | 2,443 | |||||||
NOPBT Margin | 14.78% | 1.68% | 0.53% | |||||||
Operating Taxes | 3,506 | 5,362 | 2,435 | |||||||
Tax Rate | 4.33% | 64.25% | 99.67% | |||||||
NOPAT | 77,557 | 2,983 | 8 | |||||||
Net income | 78,366 52.83% | 51,275 121.92% | 23,105 297.61% | |||||||
Dividends | (17,745) | (8,190) | (14,667) | |||||||
Dividend yield | 0.36% | 0.32% | 0.71% | |||||||
Proceeds from repurchase of equity | (190) | 34,458 | 791 | |||||||
BB yield | 0.00% | -1.33% | -0.04% | |||||||
Debt | ||||||||||
Debt current | 256,000 | 157,000 | 157,000 | |||||||
Long-term debt | (7,976) | 110,000 | ||||||||
Deferred revenue | 7,976 | 7,739 | ||||||||
Other long-term liabilities | 40,216 | 30,072 | (1,227) | |||||||
Net debt | 181,983 | 113,071 | 239,115 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 163,224 | 129,531 | 85,706 | |||||||
CAPEX | (116,374) | (169,173) | (127,430) | |||||||
Cash from investing activities | (195,072) | (122,019) | (125,700) | |||||||
Cash from financing activities | 81,066 | 1,265 | 38,124 | |||||||
FCF | 15,022 | (33,564) | (25,097) | |||||||
Balance | ||||||||||
Cash | 74,017 | 25,224 | 17,038 | |||||||
Long term investments | 10,729 | 10,847 | ||||||||
Excess cash | 46,594 | 11,080 | 4,643 | |||||||
Stockholders' equity | 765,225 | 562,500 | 392,540 | |||||||
Invested Capital | 867,358 | 744,062 | 668,966 | |||||||
ROIC | 9.63% | 0.42% | 0.00% | |||||||
ROCE | 8.84% | 1.10% | 0.36% | |||||||
EV | ||||||||||
Common stock shares outstanding | 13,652 | 13,419 | 12,684 | |||||||
Price | 360.50 87.37% | 192.40 18.04% | 163.00 2.77% | |||||||
Market cap | 4,921,456 90.62% | 2,581,751 24.87% | 2,067,487 3.04% | |||||||
EV | 5,103,439 | 2,694,822 | 2,306,602 | |||||||
EBITDA | 155,929 | 86,905 | 70,524 | |||||||
EV/EBITDA | 32.73 | 31.01 | 32.71 | |||||||
Interest | 5,038 | 2,310 | 2,265 | |||||||
Interest/NOPBT | 6.21% | 27.68% | 92.71% |